REG - Tissue Regenix Group - Publication of circular and notice of GM

Tissue RegenixAnnouncement

26/05/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200526:nRSZ9069Na

RNS Number : 9069N  Tissue Regenix Group PLC  26 May 2020

26 May 2020

Tissue Regenix Group plc

("Tissue Regenix", the "Group" or the "Company")

 

Publication of circular and notice of General Meeting

 

Tissue Regenix announces that a circular containing further information on its
recent fundraise (the "Circular") was posted to Shareholders on Friday 22 May.
The Circular also contains a notice of General Meeting (the "General Meeting")
and accompanying form of proxy.

 

The General Meeting will be held at the offices of Squire Patton Boggs (UK)
LLP, 6 Wellington Place, Leeds at 12 noon on 9 June 2020.

 

The UK Government passed into law mandatory measures in order to reduce the
transmission of COVID-19. These mandatory measures prohibit, amongst other
things, individuals engaging in non-essential travel and public gatherings of
more than two people, save where the gathering is essential for work purposes
(the "Stay at Home Measures").

 

The Company is required to hold the General Meeting in order to implement the
planned fundraise. However the Stay at Home Measures will significantly
restrict our ability to follow a standard shareholder meeting format. In order
to ensure shareholders can comply with the Stay at Home Measures the Board has
concluded that shareholders should not plan to attend the General Meeting in
person. It is currently intended that the General Meeting will be held with
only the minimum number of shareholders present as required to form a quorum
under the Company's Articles of Association, and who are essential for the
business of the General Meeting to be conducted.

 

The results of the votes on the proposed resolutions will be announced in the
normal way as soon as practicable after the conclusion of the General Meeting.

 

Having regard to their own safety and that of others, shareholders are
respectfully asked to comply with the Stay at Home Measures and not make plans
to attend the General Meeting. To ensure the safety of the limited number of
people whose attendance is essential, the Company will not be able to allow
other shareholders to gain access to the General Meeting on the day. Given the
restrictions on travel and as to how the meeting itself may be conducted,
shareholders are strongly encouraged to exercise their right to vote and to
submit a proxy as early as possible.

 

The Circular, notice of General Meeting and accompanying form of proxy, are
also available on the Company's website, www.tissueregenix.com
(http://www.tissueregenix.com) , in accordance with AIM Rule 20.

For more information:

 

 Tissue Regenix Group plc                                       Tel: 0330 430 3073 / 07920272441

 Caitlin Pearson, Head of Communications

 Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)  Tel:  0207 710 7600

 Jonathan Senior  / Ben Maddison / Alex Price

 FTI Consulting                                                 Tel: 0203 727 1000

 Simon Conway / Victoria Foster Mitchell / Mary Whittow

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of
regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out
from the University of Leeds, UK. The Company's patented decellularisation
('dCELL(®)') technology removes DNA and other cellular material from animal
and human soft tissue leaving an acellular tissue scaffold which is not
rejected by the patient's body and can then be used to repair diseased or worn
out body parts. Current applications address many critical clinical needs such
as sports medicine, heart valve replacement and wound care.

 

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the
United States - 'Tissue Regenix Wound Care Inc.' and January 2016 saw the
establishment of joint venture GBM-V, a multi- tissue bank based in Rostock,
Germany.

 

In August 2017 Tissue Regenix acquired CellRight Technologies(®), a biotech
company that specialises in regenerative medicine and is dedicated to the
development of innovative osteoinductive and wound care scaffolds that enhance
healing opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general orthopedic, foot
& ankle, dental, and sports medicine surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NOGAFMATMTTTMAM